ICLR up +0.86% percent Today $ICLR High is at 54.2
Post# of 37
Posted On: 11/11/2014 3:51:12 PM
ICLR up +0.86% percent Today $ICLR High is at 54.20 and the Low 53.22 with current volume of 161,539.
Recent News posted below.
Icon Plc ICLR other info.
http://investorshangout.com/Icon-Plc-ICLR-54412/
ICLR Icon Plc Recent Headline News
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 54.82 (+0.32), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Should You Get Rid of Air Methods (AIRM) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:42AM CST
Air Methods has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
AIRM: 43.34 (-0.14), Q: 56.53 (-0.69), BEAT: 8.24 (+0.04), ICLR: 53.45 (+0.11)
Air Methods (AIRM) Crumbles: Stock Falls by 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:39AM CST
Shares of Air Methods (AIRM) fell by nearly 8% on the day. This continues the recent trend for AIRM, as the stock is now down over 23% since Oct 10. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue.
BGMD: 0.47 (+0.03), AIRM: 43.34 (-0.14), BEAT: 8.24 (+0.04), ICLR: 53.45 (+0.11)
MedAssets Beats on Q3 Earnings, Revenues; Both Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:55AM CST
MedAssets, Inc. (MDAS) reported adjusted earnings per share (EPS) of 29 cents in the third quarter of 2014, beating the Zacks Consensus Estimate by couple of cents.
BGMD: 0.47 (+0.03), BEAT: 8.24 (+0.04), MDAS: 20.04 (-0.04), ICLR: 53.45 (+0.11)
PAREXEL International Beats Q1 Earnings, Misses Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:48AM CST
PAREXEL International (PRXL) reported adjusted earnings per share of 65 cents in the first quarter of fiscal 2015, which beat both the Zacks Consensus Estimate of 58 cents and the year-ago earnings of 45 cents.
BGMD: 0.47 (+0.03), PRXL: 54.82 (+0.32), BEAT: 8.24 (+0.04), ICLR: 53.45 (+0.11)
ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired Bacterial Pneumonia Trials
Business Wire - Thu Nov 06, 5:11AM CST
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US Food & Drug Administration (FDA) to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).
ICLR: 53.45 (+0.11)
Covance to be Acquired by LabCorp, Shares Surge 25.9% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:15PM CST
Drug-development company Covance Inc.'s (CVD) share price jumped 25.9% to close at $110.57 yesterday
BEAT: 8.24 (+0.04), LH: 99.93 (-1.05), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Covance Q3 Guidance Narrowed on In-Line Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:20PM CST
Covance (CVD) reported mixed third-quarter 2014 financial results, with the bottom line exceeding the Zacks Consensus Estimate and the top line missing the same.
BEAT: 8.24 (+0.04), LH: 99.93 (-1.05), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Strength Seen in Covance (CVD): Stock Surges 25.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:25AM CST
Covance (CVD) was a big mover last session, with shares surging nearly 26% on the day.
BEAT: 8.24 (+0.04), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Time to Focus on ICON Public Limited (ICLR) for Strong Earnings Growth Potential - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:53AM CDT
ICON Public Limited saw EPS growth of 77% last year, and might be well-positioned for future earnings growth.
ICLR: 53.45 (+0.11)
Omnicare Beats on Q3 Earnings and Sales, Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 11:40AM CDT
Omnicare Inc. (OCR) reported better-than-expected third quarter 2014 results.
PMC: 24.92 (-0.42), OCR: 68.94 (+0.21), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11)
ACRO Establishing CRO Forum To Interact with TransCelerate BioPharma Inc.
Business Wire - Mon Oct 27, 9:49AM CDT
The Association of Clinical Research Organizations today announced plans to constitute a CRO Forum in order to provide a formal mechanism for the CRO industry to furnish input into the work of TransCelerate BioPharma Inc. The CRO Forum, expected to commence operation in January 2015, is open to all CROs and participation is included as a benefit of ACRO membership.
ICLR: 53.45 (+0.11)
Healthways Earnings and Revenues in Line, View Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 9:10AM CDT
Healthways Inc. (HWAY) affirmed its 2014 financial guidance and expects adjusted earnings in the range of 11 to 26 cents per share for 2014.
BGMD: 0.47 (+0.03), HWAY: 15.11 (-0.05), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11)
Icon's (ICLR) CEO Ciaran Murray On Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 2:39PM CDT
ICLR: 53.45 (+0.11)
ICON ups earnings guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 8:46AM CDT
ICLR: 53.45 (+0.11)
Icon beats by $0.09, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 5:09AM CDT
ICLR: 53.45 (+0.11)
ICON Reports Third Quarter 2014 and Increases Earnings Guidance
Business Wire - Wed Oct 22, 5:01AM CDT
--Net revenue increased 14.1% year on year to $388 million.
ICLR: 53.45 (+0.11)
Is a Surprise Coming for ICON Public Limited (ICLR) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:48AM CDT
ICON Public Limited is poised to beat at earnings as it has a positive ESP and a better Zacks Rank that shows positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns
ICLR: 53.45 (+0.11)
Shares of ICLR Up 31.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 10, 9:42AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on May 19th, 2014 at $42.22. In approximately 5 months, ICON has returned 31.42% as of today's recent price of $55.49.
ICLR: 53.45 (+0.11)
Downgrade Alert for ICON (ICLR)
Comtex SmarTrend(R) - Fri Oct 10, 6:57AM CDT
ICON (NASDAQ:ICLR) was downgraded from Buy to Neutral at ISI Group today. The stock closed yesterday at $56.95 on volume of 427,000 shares, below average daily volume of 477,000. ICON (NASDAQ:ICLR) has potential upside of 7.9% based on a current price of $56.95 and analysts' consensus price target of $61.46. The stock should discover initial support at its 50-day moving average (MA) of $53.82 and subsequent support at its 200-day MA of $46.59.
ICLR: 53.45 (+0.11)
Recent News posted below.
Icon Plc ICLR other info.
http://investorshangout.com/Icon-Plc-ICLR-54412/
ICLR Icon Plc Recent Headline News
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 54.82 (+0.32), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Should You Get Rid of Air Methods (AIRM) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:42AM CST
Air Methods has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
AIRM: 43.34 (-0.14), Q: 56.53 (-0.69), BEAT: 8.24 (+0.04), ICLR: 53.45 (+0.11)
Air Methods (AIRM) Crumbles: Stock Falls by 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:39AM CST
Shares of Air Methods (AIRM) fell by nearly 8% on the day. This continues the recent trend for AIRM, as the stock is now down over 23% since Oct 10. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue.
BGMD: 0.47 (+0.03), AIRM: 43.34 (-0.14), BEAT: 8.24 (+0.04), ICLR: 53.45 (+0.11)
MedAssets Beats on Q3 Earnings, Revenues; Both Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:55AM CST
MedAssets, Inc. (MDAS) reported adjusted earnings per share (EPS) of 29 cents in the third quarter of 2014, beating the Zacks Consensus Estimate by couple of cents.
BGMD: 0.47 (+0.03), BEAT: 8.24 (+0.04), MDAS: 20.04 (-0.04), ICLR: 53.45 (+0.11)
PAREXEL International Beats Q1 Earnings, Misses Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:48AM CST
PAREXEL International (PRXL) reported adjusted earnings per share of 65 cents in the first quarter of fiscal 2015, which beat both the Zacks Consensus Estimate of 58 cents and the year-ago earnings of 45 cents.
BGMD: 0.47 (+0.03), PRXL: 54.82 (+0.32), BEAT: 8.24 (+0.04), ICLR: 53.45 (+0.11)
ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired Bacterial Pneumonia Trials
Business Wire - Thu Nov 06, 5:11AM CST
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US Food & Drug Administration (FDA) to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).
ICLR: 53.45 (+0.11)
Covance to be Acquired by LabCorp, Shares Surge 25.9% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:15PM CST
Drug-development company Covance Inc.'s (CVD) share price jumped 25.9% to close at $110.57 yesterday
BEAT: 8.24 (+0.04), LH: 99.93 (-1.05), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Covance Q3 Guidance Narrowed on In-Line Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:20PM CST
Covance (CVD) reported mixed third-quarter 2014 financial results, with the bottom line exceeding the Zacks Consensus Estimate and the top line missing the same.
BEAT: 8.24 (+0.04), LH: 99.93 (-1.05), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Strength Seen in Covance (CVD): Stock Surges 25.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:25AM CST
Covance (CVD) was a big mover last session, with shares surging nearly 26% on the day.
BEAT: 8.24 (+0.04), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11), CVD: 100.45 (-0.42)
Time to Focus on ICON Public Limited (ICLR) for Strong Earnings Growth Potential - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:53AM CDT
ICON Public Limited saw EPS growth of 77% last year, and might be well-positioned for future earnings growth.
ICLR: 53.45 (+0.11)
Omnicare Beats on Q3 Earnings and Sales, Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 11:40AM CDT
Omnicare Inc. (OCR) reported better-than-expected third quarter 2014 results.
PMC: 24.92 (-0.42), OCR: 68.94 (+0.21), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11)
ACRO Establishing CRO Forum To Interact with TransCelerate BioPharma Inc.
Business Wire - Mon Oct 27, 9:49AM CDT
The Association of Clinical Research Organizations today announced plans to constitute a CRO Forum in order to provide a formal mechanism for the CRO industry to furnish input into the work of TransCelerate BioPharma Inc. The CRO Forum, expected to commence operation in January 2015, is open to all CROs and participation is included as a benefit of ACRO membership.
ICLR: 53.45 (+0.11)
Healthways Earnings and Revenues in Line, View Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 9:10AM CDT
Healthways Inc. (HWAY) affirmed its 2014 financial guidance and expects adjusted earnings in the range of 11 to 26 cents per share for 2014.
BGMD: 0.47 (+0.03), HWAY: 15.11 (-0.05), CRL: 64.10 (+0.17), ICLR: 53.45 (+0.11)
Icon's (ICLR) CEO Ciaran Murray On Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 2:39PM CDT
ICLR: 53.45 (+0.11)
ICON ups earnings guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 8:46AM CDT
ICLR: 53.45 (+0.11)
Icon beats by $0.09, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 5:09AM CDT
ICLR: 53.45 (+0.11)
ICON Reports Third Quarter 2014 and Increases Earnings Guidance
Business Wire - Wed Oct 22, 5:01AM CDT
--Net revenue increased 14.1% year on year to $388 million.
ICLR: 53.45 (+0.11)
Is a Surprise Coming for ICON Public Limited (ICLR) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:48AM CDT
ICON Public Limited is poised to beat at earnings as it has a positive ESP and a better Zacks Rank that shows positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns
ICLR: 53.45 (+0.11)
Shares of ICLR Up 31.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 10, 9:42AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on May 19th, 2014 at $42.22. In approximately 5 months, ICON has returned 31.42% as of today's recent price of $55.49.
ICLR: 53.45 (+0.11)
Downgrade Alert for ICON (ICLR)
Comtex SmarTrend(R) - Fri Oct 10, 6:57AM CDT
ICON (NASDAQ:ICLR) was downgraded from Buy to Neutral at ISI Group today. The stock closed yesterday at $56.95 on volume of 427,000 shares, below average daily volume of 477,000. ICON (NASDAQ:ICLR) has potential upside of 7.9% based on a current price of $56.95 and analysts' consensus price target of $61.46. The stock should discover initial support at its 50-day moving average (MA) of $53.82 and subsequent support at its 200-day MA of $46.59.
ICLR: 53.45 (+0.11)
(0)
(0)ICON plc (ICLR) Stock Research Links
Scroll down for more posts ▼